August 14, 2020
1 min read
August is Psoriasis Awareness Month, a time dedicated to sharing information about psoriasis, its manifestations and its treatments.
In the first half of 2020, Healio covered meeting news, journal articles and breaking FDA news regarding psoriasis. Here are the top five most-read psoriasis articles from the past few months:
JAK inhibitors show promise in psoriasis, atopic dermatitis
JAK inhibitors are being studied to treat patients with psoriasis and atopic dermatitis, with many showing promising outcomes. Read more.
AAD/NPF provide exhaustive recommendations for psoriasis treatment
Experts from the American Academy of Dermatology and the National Psoriasis Foundation teamed up to offer an extensive set of guidelines for the management of psoriasis. Read more.
FDA approves Taltz for pediatric psoriasis
The FDA has approved a supplemental biologics license application for ixekizumab in pediatric patients with moderate to severe plaque psoriasis. Read more.
Ixekizumab, brodalumab show strongest clinical benefit in psoriasis
Both ixekizumab and brodalumab were associated with better clinical benefit than other biologic therapies over 12 weeks or 16 weeks of treatment for psoriasis. Read more.
Psoriasis linked to increased risk for lymphomas, keratinocyte cancer
Patients with psoriasis carry a slightly increased risk for cancer, particularly keratinocyte cancer and lymphomas. Read more.